Treatment of hepatitis B in patients with chronic kidney disease Chrysoula L. Pipili, George V. Papatheodoridis, Evangelos C. Cholongitas  Kidney International  Volume 84, Issue 5, Pages 880-885 (November 2013) DOI: 10.1038/ki.2013.249 Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 1 Proposed algorithm for the management of patients with hepatitis B virus (HBV)–related nephropathy. ACE, angiotensin-converting enzyme; BP, blood pressure; GFR, glomerular filtration rate; NA, nucleos(t)ide analog; Peg IFN-α, pegylated interferon-α. Kidney International 2013 84, 880-885DOI: (10.1038/ki.2013.249) Copyright © 2013 International Society of Nephrology Terms and Conditions

Figure 2 Proposed algorithm for the management of patients with hepatitis B virus (HBV) infection and kidney diseases. *Newer NA is entecavir, tenofovir, and telbivudine. Among the newer NAs, entecavir may be preferred for most NA-naive patients because of its high potency, high genetic barrier to resistance, and favorable renal safety profile; tenofovir may be preferred in cases with prior lamivudine or telbivudine resistance due to the low efficacy of entecavir in this setting; telbivudine warrants further evaluation because of its potentially beneficial effect on renal function. **Lamivudine is only applicable in cases of short treatment duration. HBIG, hepatitis B immunoglobulin; HBsAg, hepatitis B surface antigen; NA, nucleos(t)ide analog; RT, renal transplantation. Kidney International 2013 84, 880-885DOI: (10.1038/ki.2013.249) Copyright © 2013 International Society of Nephrology Terms and Conditions